The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Cholesterol-Lowering Drugs-Global Market Insights and Sales Trends 2024
Synopsis
The global Cholesterol-Lowering Drugs market size is expected to reach US$ 21170 million by 2029, growing at a CAGR of 2.8% from 2023 to 2029. The market is mainly driven by the significant applications of Cholesterol-Lowering Drugs in various end use industries. The expanding demands from the Hospital, Household and Other, are propelling Cholesterol-Lowering Drugs market. Statins, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Cholesterol Absorption Inhibitors segment is estimated at % CAGR for the next seven-year period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Objectives
This report provides market insight on the different segments, by manufacturers, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Cholesterol-Lowering Drugs, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Cholesterol-Lowering Drugs market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Cholesterol-Lowering Drugs market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Cholesterol-Lowering Drugs sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Cholesterol-Lowering Drugs covered in this report include AstraZeneca, Merck, Pfizer, Kowa, Daiichi Sankyo, AbbVie, Novartis, Sanofi and Amgen, etc.
The global Cholesterol-Lowering Drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
AstraZeneca
Merck
Pfizer
Kowa
Daiichi Sankyo
AbbVie
Novartis
Sanofi
Amgen
Bristol-Myers Squibb
Global Cholesterol-Lowering Drugs market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Cholesterol-Lowering Drugs market, Segment by Type:
Statins
Cholesterol Absorption Inhibitors
Fibrates
PCSK9 Inhibitors
Global Cholesterol-Lowering Drugs market, by Application
Hospital
Household
Other
Core Chapters
Chapter One: Introduces the study scope of this report, executive summary of market segments by Type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Two: Detailed analysis of Cholesterol-Lowering Drugs manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Three: Sales, revenue of Cholesterol-Lowering Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.
Chapter Four: Introduces market segments by Application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Five, Six, Seven, Eight and Nine: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.
Chapter Ten: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter Eleven: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics. Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Analysis of sales channel, distributors and customers.
Chapter Thirteen: Research Findings and Conclusion.
The global Cholesterol-Lowering Drugs market size is expected to reach US$ 21170 million by 2029, growing at a CAGR of 2.8% from 2023 to 2029. The market is mainly driven by the significant applications of Cholesterol-Lowering Drugs in various end use industries. The expanding demands from the Hospital, Household and Other, are propelling Cholesterol-Lowering Drugs market. Statins, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Cholesterol Absorption Inhibitors segment is estimated at % CAGR for the next seven-year period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Objectives
This report provides market insight on the different segments, by manufacturers, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Cholesterol-Lowering Drugs, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Cholesterol-Lowering Drugs market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Cholesterol-Lowering Drugs market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Cholesterol-Lowering Drugs sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Cholesterol-Lowering Drugs covered in this report include AstraZeneca, Merck, Pfizer, Kowa, Daiichi Sankyo, AbbVie, Novartis, Sanofi and Amgen, etc.
The global Cholesterol-Lowering Drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
AstraZeneca
Merck
Pfizer
Kowa
Daiichi Sankyo
AbbVie
Novartis
Sanofi
Amgen
Bristol-Myers Squibb
Global Cholesterol-Lowering Drugs market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Cholesterol-Lowering Drugs market, Segment by Type:
Statins
Cholesterol Absorption Inhibitors
Fibrates
PCSK9 Inhibitors
Global Cholesterol-Lowering Drugs market, by Application
Hospital
Household
Other
Core Chapters
Chapter One: Introduces the study scope of this report, executive summary of market segments by Type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Two: Detailed analysis of Cholesterol-Lowering Drugs manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Three: Sales, revenue of Cholesterol-Lowering Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.
Chapter Four: Introduces market segments by Application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Five, Six, Seven, Eight and Nine: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.
Chapter Ten: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter Eleven: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics. Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Analysis of sales channel, distributors and customers.
Chapter Thirteen: Research Findings and Conclusion.
Index1 Cholesterol-Lowering Drugs Market Overview
1.1 Cholesterol-Lowering Drugs Product Overview
1.2 Cholesterol-Lowering Drugs Market Segment by Type
1.2.1 Statins
1.2.2 Cholesterol Absorption Inhibitors
1.2.3 Fibrates
1.2.4 PCSK9 Inhibitors
1.3 Global Cholesterol-Lowering Drugs Market Size by Type
1.3.1 Global Cholesterol-Lowering Drugs Market Size Overview by Type (2018-2029)
1.3.2 Global Cholesterol-Lowering Drugs Historic Market Size Review by Type (2018-2023)
1.3.3 Global Cholesterol-Lowering Drugs Forecasted Market Size by Type (2024-2029)
1.4 Key Regions Market Size Segment by Type
1.4.1 North America Cholesterol-Lowering Drugs Sales Breakdown by Type (2018-2023)
1.4.2 Europe Cholesterol-Lowering Drugs Sales Breakdown by Type (2018-2023)
1.4.3 Asia-Pacific Cholesterol-Lowering Drugs Sales Breakdown by Type (2018-2023)
1.4.4 Latin America Cholesterol-Lowering Drugs Sales Breakdown by Type (2018-2023)
1.4.5 Middle East and Africa Cholesterol-Lowering Drugs Sales Breakdown by Type (2018-2023)
2 Global Cholesterol-Lowering Drugs Market Competition by Company
2.1 Global Top Players by Cholesterol-Lowering Drugs Sales (2018-2023)
2.2 Global Top Players by Cholesterol-Lowering Drugs Revenue (2018-2023)
2.3 Global Top Players by Cholesterol-Lowering Drugs Price (2018-2023)
2.4 Global Top Manufacturers Cholesterol-Lowering Drugs Manufacturing Base Distribution, Sales Area, Product Type
2.5 Cholesterol-Lowering Drugs Market Competitive Situation and Trends
2.5.1 Cholesterol-Lowering Drugs Market Concentration Rate (2018-2023)
2.5.2 Global 5 and 10 Largest Manufacturers by Cholesterol-Lowering Drugs Sales and Revenue in 2022
2.6 Global Top Manufacturers by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Cholesterol-Lowering Drugs as of 2022)
2.7 Date of Key Manufacturers Enter into Cholesterol-Lowering Drugs Market
2.8 Key Manufacturers Cholesterol-Lowering Drugs Product Offered
2.9 Mergers & Acquisitions, Expansion
3 Cholesterol-Lowering Drugs Status and Outlook by Region
3.1 Global Cholesterol-Lowering Drugs Market Size and CAGR by Region: 2018 VS 2022 VS 2029
3.2 Global Cholesterol-Lowering Drugs Historic Market Size by Region
3.2.1 Global Cholesterol-Lowering Drugs Sales in Volume by Region (2018-2023)
3.2.2 Global Cholesterol-Lowering Drugs Sales in Value by Region (2018-2023)
3.2.3 Global Cholesterol-Lowering Drugs Sales (Volume & Value) Price and Gross Margin (2018-2023)
3.3 Global Cholesterol-Lowering Drugs Forecasted Market Size by Region
3.3.1 Global Cholesterol-Lowering Drugs Sales in Volume by Region (2024-2029)
3.3.2 Global Cholesterol-Lowering Drugs Sales in Value by Region (2024-2029)
3.3.3 Global Cholesterol-Lowering Drugs Sales (Volume & Value), Price and Gross Margin (2024-2029)
4 Global Cholesterol-Lowering Drugs by Application
4.1 Cholesterol-Lowering Drugs Market Segment by Application
4.1.1 Hospital
4.1.2 Household
4.1.3 Other
4.2 Global Cholesterol-Lowering Drugs Market Size by Application
4.2.1 Global Cholesterol-Lowering Drugs Market Size Overview by Application (2018-2029)
4.2.2 Global Cholesterol-Lowering Drugs Historic Market Size Review by Application (2018-2023)
4.2.3 Global Cholesterol-Lowering Drugs Forecasted Market Size by Application (2024-2029)
4.3 Key Regions Market Size Segment by Application
4.3.1 North America Cholesterol-Lowering Drugs Sales Breakdown by Application (2018-2023)
4.3.2 Europe Cholesterol-Lowering Drugs Sales Breakdown by Application (2018-2023)
4.3.3 Asia-Pacific Cholesterol-Lowering Drugs Sales Breakdown by Application (2018-2023)
4.3.4 Latin America Cholesterol-Lowering Drugs Sales Breakdown by Application (2018-2023)
4.3.5 Middle East and Africa Cholesterol-Lowering Drugs Sales Breakdown by Application (2018-2023)
5 North America Cholesterol-Lowering Drugs by Country
5.1 North America Cholesterol-Lowering Drugs Historic Market Size by Country
5.1.1 North America Cholesterol-Lowering Drugs Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
5.1.2 North America Cholesterol-Lowering Drugs Sales in Volume by Country (2018-2023)
5.1.3 North America Cholesterol-Lowering Drugs Sales in Value by Country (2018-2023)
5.2 North America Cholesterol-Lowering Drugs Forecasted Market Size by Country
5.2.1 North America Cholesterol-Lowering Drugs Sales in Volume by Country (2024-2029)
5.2.2 North America Cholesterol-Lowering Drugs Sales in Value by Country (2024-2029)
6 Europe Cholesterol-Lowering Drugs by Country
6.1 Europe Cholesterol-Lowering Drugs Historic Market Size by Country
6.1.1 Europe Cholesterol-Lowering Drugs Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
6.1.2 Europe Cholesterol-Lowering Drugs Sales in Volume by Country (2018-2023)
6.1.3 Europe Cholesterol-Lowering Drugs Sales in Value by Country (2018-2023)
6.2 Europe Cholesterol-Lowering Drugs Forecasted Market Size by Country
6.2.1 Europe Cholesterol-Lowering Drugs Sales in Volume by Country (2024-2029)
6.2.2 Europe Cholesterol-Lowering Drugs Sales in Value by Country (2024-2029)
7 Asia-Pacific Cholesterol-Lowering Drugs by Region
7.1 Asia-Pacific Cholesterol-Lowering Drugs Historic Market Size by Region
7.1.1 Asia-Pacific Cholesterol-Lowering Drugs Market Size Growth Rate (CAGR) by Region: 2018 VS 2022 VS 2029
7.1.2 Asia-Pacific Cholesterol-Lowering Drugs Sales in Volume by Region (2018-2023)
7.1.3 Asia-Pacific Cholesterol-Lowering Drugs Sales in Value by Region (2018-2023)
7.2 Asia-Pacific Cholesterol-Lowering Drugs Forecasted Market Size by Region
7.2.1 Asia-Pacific Cholesterol-Lowering Drugs Sales in Volume by Region (2024-2029)
7.2.2 Asia-Pacific Cholesterol-Lowering Drugs Sales in Value by Region (2024-2029)
8 Latin America Cholesterol-Lowering Drugs by Country
8.1 Latin America Cholesterol-Lowering Drugs Historic Market Size by Country
8.1.1 Latin America Cholesterol-Lowering Drugs Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
8.1.2 Latin America Cholesterol-Lowering Drugs Sales in Volume by Country (2018-2023)
8.1.3 Latin America Cholesterol-Lowering Drugs Sales in Value by Country (2018-2023)
8.2 Latin America Cholesterol-Lowering Drugs Forecasted Market Size by Country
8.2.1 Latin America Cholesterol-Lowering Drugs Sales in Volume by Country (2024-2029)
8.2.2 Latin America Cholesterol-Lowering Drugs Sales in Value by Country (2024-2029)
9 Middle East and Africa Cholesterol-Lowering Drugs by Country
9.1 Middle East and Africa Cholesterol-Lowering Drugs Historic Market Size by Country
9.1.1 Middle East and Africa Cholesterol-Lowering Drugs Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
9.1.2 Middle East and Africa Cholesterol-Lowering Drugs Sales in Volume by Country (2018-2023)
9.1.3 Middle East and Africa Cholesterol-Lowering Drugs Sales in Value by Country (2018-2023)
9.2 Middle East and Africa Cholesterol-Lowering Drugs Forecasted Market Size by Country
9.2.1 Middle East and Africa Cholesterol-Lowering Drugs Sales in Volume by Country (2024-2029)
9.2.2 Middle East and Africa Cholesterol-Lowering Drugs Sales in Value by Country (2024-2029)
10 Company Profiles
10.1 AstraZeneca
10.1.1 AstraZeneca Company Information
10.1.2 AstraZeneca Introduction and Business Overview
10.1.3 AstraZeneca Cholesterol-Lowering Drugs Sales, Revenue and Gross Margin (2018-2023)
10.1.4 AstraZeneca Cholesterol-Lowering Drugs Products Offered
10.1.5 AstraZeneca Recent Development
10.2 Merck
10.2.1 Merck Company Information
10.2.2 Merck Introduction and Business Overview
10.2.3 Merck Cholesterol-Lowering Drugs Sales, Revenue and Gross Margin (2018-2023)
10.2.4 Merck Cholesterol-Lowering Drugs Products Offered
10.2.5 Merck Recent Development
10.3 Pfizer
10.3.1 Pfizer Company Information
10.3.2 Pfizer Introduction and Business Overview
10.3.3 Pfizer Cholesterol-Lowering Drugs Sales, Revenue and Gross Margin (2018-2023)
10.3.4 Pfizer Cholesterol-Lowering Drugs Products Offered
10.3.5 Pfizer Recent Development
10.4 Kowa
10.4.1 Kowa Company Information
10.4.2 Kowa Introduction and Business Overview
10.4.3 Kowa Cholesterol-Lowering Drugs Sales, Revenue and Gross Margin (2018-2023)
10.4.4 Kowa Cholesterol-Lowering Drugs Products Offered
10.4.5 Kowa Recent Development
10.5 Daiichi Sankyo
10.5.1 Daiichi Sankyo Company Information
10.5.2 Daiichi Sankyo Introduction and Business Overview
10.5.3 Daiichi Sankyo Cholesterol-Lowering Drugs Sales, Revenue and Gross Margin (2018-2023)
10.5.4 Daiichi Sankyo Cholesterol-Lowering Drugs Products Offered
10.5.5 Daiichi Sankyo Recent Development
10.6 AbbVie
10.6.1 AbbVie Company Information
10.6.2 AbbVie Introduction and Business Overview
10.6.3 AbbVie Cholesterol-Lowering Drugs Sales, Revenue and Gross Margin (2018-2023)
10.6.4 AbbVie Cholesterol-Lowering Drugs Products Offered
10.6.5 AbbVie Recent Development
10.7 Novartis
10.7.1 Novartis Company Information
10.7.2 Novartis Introduction and Business Overview
10.7.3 Novartis Cholesterol-Lowering Drugs Sales, Revenue and Gross Margin (2018-2023)
10.7.4 Novartis Cholesterol-Lowering Drugs Products Offered
10.7.5 Novartis Recent Development
10.8 Sanofi
10.8.1 Sanofi Company Information
10.8.2 Sanofi Introduction and Business Overview
10.8.3 Sanofi Cholesterol-Lowering Drugs Sales, Revenue and Gross Margin (2018-2023)
10.8.4 Sanofi Cholesterol-Lowering Drugs Products Offered
10.8.5 Sanofi Recent Development
10.9 Amgen
10.9.1 Amgen Company Information
10.9.2 Amgen Introduction and Business Overview
10.9.3 Amgen Cholesterol-Lowering Drugs Sales, Revenue and Gross Margin (2018-2023)
10.9.4 Amgen Cholesterol-Lowering Drugs Products Offered
10.9.5 Amgen Recent Development
10.10 Bristol-Myers Squibb
10.10.1 Bristol-Myers Squibb Company Information
10.10.2 Bristol-Myers Squibb Introduction and Business Overview
10.10.3 Bristol-Myers Squibb Cholesterol-Lowering Drugs Sales, Revenue and Gross Margin (2018-2023)
10.10.4 Bristol-Myers Squibb Cholesterol-Lowering Drugs Products Offered
10.10.5 Bristol-Myers Squibb Recent Development
11 Upstream, Opportunities, Challenges, Risks and Influences Factors Analysis
11.1 Cholesterol-Lowering Drugs Key Raw Materials
11.1.1 Key Raw Materials
11.1.2 Key Raw Materials Price
11.1.3 Raw Materials Key Suppliers
11.2 Manufacturing Cost Structure
11.2.1 Raw Materials
11.2.2 Labor Cost
11.2.3 Manufacturing Expenses
11.3 Cholesterol-Lowering Drugs Industrial Chain Analysis
11.4 Cholesterol-Lowering Drugs Market Dynamics
11.4.1 Cholesterol-Lowering Drugs Industry Trends
11.4.2 Cholesterol-Lowering Drugs Market Drivers
11.4.3 Cholesterol-Lowering Drugs Market Challenges
11.4.4 Cholesterol-Lowering Drugs Market Restraints
12 Market Strategy Analysis, Distributors
12.1 Sales Channel
12.2 Cholesterol-Lowering Drugs Distributors
12.3 Cholesterol-Lowering Drugs Downstream Customers
13 Research Findings and Conclusion
14 Appendix
14.1 Research Methodology
14.1.1 Methodology/Research Approach
14.1.2 Data Source
14.2 Author Details
14.3 Disclaimer
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
